These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22565239)

  • 1. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
    AlJaroudi WA; Alraies MC; Cerquiera MD; Jaber WA
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):341-8. PubMed ID: 23208701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.
    Cabrera R; Husain Z; Palani G; Karthikeyan AS; Choudhry Z; Dhanalakota S; Peterson E; Ananthasubramaniam K
    J Nucl Cardiol; 2013 Jun; 20(3):336-43; quiz 344-5. PubMed ID: 23430361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.
    Parker MW; Morales DC; Slim HB; Ahlberg AW; Katten DM; Cyr G; Mathur S; Ardestani A; Barmpouletos D; Iyah GS; Borer SM; Heller GV
    J Nucl Cardiol; 2013 Apr; 20(2):185-96. PubMed ID: 23188626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.
    Thompson RC; Patil H; Thompson EC; Thomas GS; Al-Amoodi M; Kennedy KF; Bybee KA; Iain McGhie A; O'Keefe JH; Oakes L; Bateman TM
    J Nucl Cardiol; 2013 Apr; 20(2):214-21; quiz 222-6. PubMed ID: 23233371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of regadenoson stress testing in patients with pulmonary hypertension.
    Moles VM; Cascino T; Saleh A; Mikhova K; Lazarus JJ; Ghannam M; Yun HJ; Konerman M; Weinberg RL; Ficaro EP; Corbett JR; McLaughlin VV; Murthy VL
    J Nucl Cardiol; 2018 Jun; 25(3):820-827. PubMed ID: 27896702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Ballany W; Mansour K; Morales Demori R; Al-Amoodi M; Doukky R
    J Nucl Cardiol; 2014 Jun; 21(3):496-502. PubMed ID: 24519563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
    Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results.
    Janvier L; Pinaquy J; Douard H; Karcher G; Bordenave L
    J Nucl Cardiol; 2017 Feb; 24(1):34-40. PubMed ID: 26542990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.
    Ross MI; Wu E; Wilkins JT; Gupta D; Shen S; Aulwes D; Montero K; Holly TA
    J Nucl Cardiol; 2013 Apr; 20(2):197-204. PubMed ID: 23404232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging.
    Doukky R; Nigatu A; Khan R; Anokwute C; Fughhi I; Ayoub A; Iskander F; Iskander M; Kola S; Sahyouni M; Karavolos K; Hota BN; Gomez J
    J Nucl Cardiol; 2020 Oct; 27(5):1521-1532. PubMed ID: 30132187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging.
    Katsikis A; Kyrozi E; Manira V; Theodorakos A; Malamitsi J; Tsapaki V; Iakovou I; Voudris V; Kolovou G; Koutelou M
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2590-2600. PubMed ID: 31414207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.
    Cavalcante JL; Barboza J; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):628-33. PubMed ID: 21626090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
    Palani G; Husain Z; Salinas RC; Karthikeyan V; Karthikeyan AS; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):605-11. PubMed ID: 21541818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of regadenoson in patients with severe chronic obstructive pulmonary disease.
    Salgado-Garcia C; Jimenez-Heffernan A; Ramos-Font C; Lopez-Martin J; Sanchez-de-Mora E; Aroui T; Lopez-Aguilar R; Rivera-de-Los-Santos F; Ruiz-Frutos C
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):283-6. PubMed ID: 27160774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPD1 polymorphism and response to regadenoson.
    Saab R; Zouk AN; Mastouri R; Skaar TC; Philips S; Kreutz RP
    Pharmacogenomics; 2015 Nov; 16(16):1807-15. PubMed ID: 26554440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.
    Zhao G; Serpllion S; Shryock J; Messina E; Xu X; Ochoa M; Belardinelli L; Hintze TH
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):467-73. PubMed ID: 19033827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
    Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ
    Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.